secwatch.observer — SEC 8-K summary
======================================

Issuer:     Indaptus Therapeutics, Inc. (INDP)
CIK:        0001857044
Form:       8-K
Filed at:   2026-01-20T23:59:59+00:00
Accession:  0001493152-26-002850
Event type: leadership
Sentiment:  negative
Materiality: 0.60
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Indaptus cuts co-CEO and CSO salaries to $60K/year; director rescinds resignation
--------------------------------------------------------------------------------

- Co-CEO Jeffrey A. Meckler and CSO Michael J. Newman salaries reduced to $60,000 per annum effective Jan 15, 2026.
- Director Anthony Maddaluna rescinded his prior resignation and will remain on the Board, including Compensation and Nominating committees.
- Salary adjustments are for the remainder of the 2026 calendar year and follow prior employment modifications from Dec 2025.
- The reductions are part of a cost-saving measure tied to a securities purchase agreement with investor David E. Lazar.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1857044/000149315226002850/0001493152-26-002850-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1857044/000149315226002850/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-002850

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer